Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer

The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patien...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1998-06, Vol.77 (11), p.2008-2011
Main Authors: Peppercorn, PD, Reznek, RH, Wilson, P, Slevin, ML, Gupta, RK
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
clinical-oncology
Colorectal Neoplasms - diagnostic imaging
Colorectal Neoplasms - drug therapy
Colorectal Neoplasms - physiopathology
Drug Resistance
Drug toxicity and drugs side effects treatment
Epidemiology
Fatty Liver - diagnostic imaging
Female
Fluorouracil - therapeutic use
Humans
Leucovorin - therapeutic use
Liver - physiopathology
Male
Medical sciences
Middle Aged
Molecular Medicine
Oncology
Pharmacology. Drug treatments
Tomography, X-Ray Computed
Toxicity: digestive system
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The frequency and severity of fatty infiltration of the liver in patients receiving 5-fluorouracil (5-FU) and folinic acid has not been documented systematically. Its development can result in difficulty assessing disease progression, and treatment may be altered inappropriately. Twenty-seven patients with colon cancer and liver metastases receiving 5-FU and folinic acid were studied with computerized tomography (CT) before treatment and after six or 12 cycles of chemotherapy. Forty-seven per cent of patients developed hepatic steatosis during treatment. There was no correlation between development of hepatic steatosis and the dose of chemotherapy or the liver function tests. Hepatic steatosis occurs commonly in patients receiving 5-FU and folinic acid and can be severe. Its development can make hepatic metastases difficult to assess and if its benign nature is not appreciated treatment may be inappropriately altered.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1998.333